NCT02444637View on ClinicalTrials.gov

Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Alzheimer DiseaseCVA (Cerebrovascular Accident)
Interventions
DRUG

Rivastigmine

Trial Locations (1)

308433

National Neuroscience Institute, Singapore

Sponsors
All Listed Sponsors
lead

National Neuroscience Institute

OTHER